Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis

Journal Title: UNKNOWN - Year 2017, Vol 23, Issue 4

Abstract

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system and is characterized by inflammation, demyelination, and axonal loss. Fingolimod is the first oral drug for the treatment of MS approved by the United States Food and Drug Administration, European Union countries, and various other countries. The compound exerts its effect via interaction with lysophospholipid receptors known as sphingosine-1 phosphate receptors. Although fingolimod has a very convenient daily oral dosing, it may cause development of bradycardia at the first dose, macular edema, infection, all of which require attention. Randomized double-blind clinical trials have shown that fingolimod significantly reduces relapse rates and is beneficial in brain magnetic resonance imaging measures when compared with both placebo and intramuscular interferon β-1a. This review describes the characteristics of fingolimod concerning its efficacy, safety, and tolerability in the clinical context of the management of MS.

Authors and Affiliations

Burcu Altunrende, Erkingül Birday, Mithat Kasap, Gülşen Akman Demir

Keywords

Related Articles

Serum Lipid Profiles, Relationship Between Paraoxonase/Arylesterase Activity and High-density Lipoprotein Levels in Patients with Migraine

Objective: Paraoxonase 1 (PON1) is associated with high-density lipoprotein (HDL) and inhibits low-density lipoprotein (LDL) oxidation. The antioxidant and antiatherogenic characteristics of HDL are attributed to this fe...

Screening Inherited Metabolic Disorder in Children with Intellectual Disability and Epilepsy

Objective: To indicate the benefits of the screening of inherited metabolic disorders in patients with epilepsy, global developmental delay, and intellectual disability. Materials and Methods: The medical records of 1100...

The Effect of Different ApoE Genotypes and Other Risk Factors on Obstructive Sleep Apnea Syndrome Formation

Objective: Obstructive sleep apnea syndrome (OSAS) is a disorder characterized by partial or complete narrowing of the pharyngeal airway during sleep. In this study it was aimed to investigate the relation between OSAS a...

Neurosyphilis Presenting with Ptosis and Diplopia as the First Complaints: Case Report

Syphilis is a spirochete disease that occurs due to Treponema pallidum infection. It can be sexually transmitted and can be transmitted from mother to baby vertically. Neurological involvement is more common in the late...

Download PDF file
  • EP ID EP276790
  • DOI 10.4274/tnd.62144
  • Views 85
  • Downloads 0

How To Cite

Burcu Altunrende, Erkingül Birday, Mithat Kasap, Gülşen Akman Demir (2017). Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis. UNKNOWN, 23(4), 176-185. https://www.europub.co.uk/articles/-A-276790